Resources Resource Type All Resources Poster (10) Presentation (5) Publication (27) Year All Years 2025 (4) 2024 (6) 2023 (6) 2022 (2) 2021 (5) 2020 (4) 2019 (1) 2018 (3) 2014 (3) 2011 (3) 2009 (1) 2007 (1) 2006 (1) 2005 (2) Search Found 42 Results May 9, 2023 CD24-Siglec interactions in inflammatory diseases Read more November 8, 2022 Dose escalation of ONC-392, a target preserving anti-CTLA4 mAb, in combination with fixed dose of pembrolizumab in patients with advanced solid tumors and dose expansion in patients with IO-resistant melanoma Read more November 8, 2022 Safety and Clinical Activities of ONC-392, a target preservinganti-CTLA-4 mAb, in Ovarian Cancer Patients Who Have Failed Multiple Lines of Systemic Therapies Read more August 22, 2022 CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder Read more July 15, 2022 CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect Read more November 10, 2021 Clinical protocol of an open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors Read more «12345»
